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Adenovirus prime, Env protein boost vaccine
protects against neutralization-resistant
SIVsmE660 variants in rhesus monkeys
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Previous studies have shown that DNA prime, Ad5 boost vaccines protect against
neutralization-sensitive but not neutralization-resistant virus variants within the SIVsmE660
swarm. Here we show that Ad prime, Env protein boost vaccines protect against
neutralization-resistant SIVsmE660 variants. We perform two studies in rhesus monkeys
with Ad35/Ad26 vectors expressing SIVmac239 Gag/Pol/Env with or without an
AS01B-adjuvanted SIVmac32H gp140 protein boost. In a repetitive, low-dose challenge study,
we observe robust protection against acquisition of infection by both Ad Alone and Ad/Env
vaccines. In a single, high-dose challenge study, only the Ad/Env vaccine affords signiﬁcant
protection against acquisition of infection. Analysis of transmitted/founder (T/F) viruses
from this study demonstrates that the Ad/Env vaccine blocks both neutralization-sensitive
and neutralization-resistant SIVsmE660 variants in rhesus monkeys with restrictive TRIM5a
alleles. These data demonstrate that the adjuvanted Env protein boost is critical for protecting
against high-dose SIVsmE660 challenge and for blocking neutralization-resistant viruses
within the SIVsmE660 swarm.
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T
he goal of an effective AIDS vaccine is to prevent
acquisition of infection following HIV-1 exposure. Most
primary HIV-1 isolates have a neutralization-resistant
phenotype. Previous studies have reported that a DNA/Ad5
vaccine partially protected against SIVsmE660 challenges but
not against SIVmac251 challenges in rhesus monkeys1. Following
the lack of efﬁcacy of the DNA/Ad5 vaccine in humans2,
the SIVsmE660 challenge model has generally been viewed
as insufﬁciently stringent for preclinical testing of AIDS vaccine
candidates. However, a follow-up study revealed that the
DNA/Ad5 vaccine only protected against highly neutralization-
sensitive viral variants within the SIVsmE660 swarm and did
not protect against neutralization-resistant viral variants within
the challenge stock3. A particular viral genotype (A/K at position
45/47 of Env) was associated with breakthrough infections, and
this ‘A/K genotype’ was associated with antibody neutralization
resistance3,4.
We have previously reported that Ad35/Ad26 vectors
expressing Gag/Pol/Env provided signiﬁcant protection against
acquisition of neutralization-resistant SIVmac251 challenges but
only when Env was included in the adenovirus vaccine5.
We further showed that addition of an AS01B-adjuvanted Env
gp140 protein boost augmented protection against neutralization-
resistant SIVmac251 challenges6.
Several simian immunodeﬁciency virus (SIV) stocks exist
for use in rhesus monkeys, each with beneﬁts and limitations.
The two most common lineages used are the molecular clone
SIVmac239 with its related isolate SIVmac251, and the molecular
clone SIVsmE543 and its related isolate SIVsmE660. These
two lineages differ by B20% in Env. Importantly, the SIVsm
lineage consists of a heterogeneous population consisting of both
neutralization-sensitive (T/R at position 45/47) and neutraliza-
tion-resistant (A/K at position 45/47) viruses. In contrast, the
SIVmac lineage is composed primarily of neutralization-resistant
(A/K) viruses7–9.
A single, high-dose (SHD) intrarectal challenge model is a
stringent model to evaluate protective efﬁcacy and provides a
robust and consistent infection that is characterized by many
more transmitted/founder (T/F) variants establishing systemic
infection than are observed in most human infections10–12.
A repetitive, low-dose (RLD) challenge model is a less stringent
model that results in fewer T/F variants establishing systemic
infection and can be used to calculate a per-exposure reduction in
acquisition risk as one measure of vaccine efﬁcacy3,5. Combining
acquisition data with an enumeration of T/F variants provides
further insight into vaccine efﬁcacy3. Whether SHD or RLD
challenge models are more predictive of clinical efﬁcacy of a
vaccine, however, remains to be deﬁned.
Identifying a viral population that can be blocked by
vaccination compared to those which can still initiate infection
is a powerful tool to identify potential mechanisms of
protection13. Genetic sieve analyses are designed to identify
viral lineages that are capable of initiating infection but have been
blocked by vaccine-induced immune responses. In human
vaccine trials, sieve analyses are limited due to the enormous
heterogeneity of HIV-1 in a population such that each patient is
infected with a unique viral genome. For these analyses, a
comparison is made of the overall genetic distance of each
breakthrough infection to the vaccine strain, as well as observing
single amino acid polymorphisms that differ between vaccinees
and placebo controls. If these polymorphisms deviate from the
vaccine strain, it is considered vaccine-induced selection13. In
rhesus monkey challenge studies, the beneﬁts of sieve analyses are
expanded since the genetic makeup of the inoculating virus itself
is known and all animals are infected with the same inoculum,
providing an important control in establishing which viral
lineages initiate infection in both vaccinated and control
animals3.
Here we show that Ad35/Ad26 vectors expressing Gag/Pol/Env
followed by an adjuvanted Env gp140 protein boost protected
against both neutralization-sensitive and neutralization-resistant
virus variants within the SIVsmE660 swarm. We performed
parallel studies using both SHD and RLD SIVsmE660 challenge
models to compare protective efﬁcacy and the number of
T/F variants, and we demonstrate that this vaccine could protect
against A/K neutralization-resistant viral variants within the
SIVsmE660 swarm by a sieve analysis.
Results
Repetitive low-dose challenge study. In Study 1 (RLD challenge
study), 36 animals were grouped into three arms (N¼ 12 per
group): Ad35/Ad26 only, Ad35/Ad26/Env or sham controls.
Vaccinated animals received 2 1010 viral particles Ad35 (ref. 14)
expressing SIVmac239 Gag/Pol/Env at week 0 and 2 1010 viral
particles Ad26 expressing the same SIVmac239 Gag/Pol/Env
inserts at week 24. In the Ad35/Ad26/Env group, animals were
boosted with 0.25mg SIVmac32H Env gp140 with GSK Adjuvant
System AS01B at weeks 36, 40 and 44. Binding antibody
titres were measured at weeks 0, 4, 28, 40, 44 and 48 (Fig. 1a;
Supplementary Table 1). Ad35/Ad26 and Ad35/Ad26/Env
vaccinated animals had antibody titres from week 4 onwards.
Following the Env protein boost, the Ad35/Ad26/Env vaccinated
animals developed B1 log higher titres of binding antibodies
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Figure 1 | Humoral and cellular immune responses. Vaccine-induced
binding antibodies titres (N¼ 12/group) were determined by SIVmac251
Env ELISA at week 0, 4, 28, 40, 44 and 48 following vaccination (a).
Cellular immune responses to SIVmac239 and SIVsmE543 Gag, Pol and Env
were determined by IFN-g ELISPOTassays at weeks 0, 4, 28, 48 and 56 and
reported as spot-forming cells (SFC) per million PBMC (b). Ad/Env (blue)
indicates animals primed with Ad35/Ad26 and boosted with adjuvanted
Env gp140 (Ad35/Ad26/Env). Ad/Ad (red) indicates animals vaccinated
with Ad35/Ad26 only. Sham controls (black) were vaccinated with
Ad35/Ad26 expressing no relevant antigens. Error bars represent s.e.m.
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than the Ad35/Ad26 vaccinated animals. Cellular immune
responses were measured by IFN-g ELISPOT assays at weeks 0, 4,
28, 48 and 56 against homologous peptides and heterologous
peptides (Fig. 1b; Supplementary Table 1). Responses to the
heterologous SIVsmE543 peptides were B2-fold lower than
responses to the homologous SIVmac239 peptides. Following
the Env protein boost, the Ad35/Ad26/Env group had higher
ELISPOT responses than Ad35/Ad26. The immunogenicity of
this vaccine essentially was comparable with our previously
published studies6.
Animals were challenged weekly for 12 weeks by a repetitive,
low-dose (RLD) challenge protocol with a 1:1,000 dilution
(930 TCID50) of our SIVsmE660 stock by the intrarectal route.
Following 12 challenges, 10 of 12 sham vaccinated animals were
infected, as compared with 3 of 12 Ad35/Ad26 vaccinees and 2 of
12 Ad35/Ad26/Env vaccinees (Fig. 2a). Both vaccinated groups
demonstrated statistically signiﬁcant protection from acquisition
of infection (Table 1). The Ad35/Ad26 group showed 75%
complete protection with a Cox proportional hazard ratio of
0.194 (0.051–0.072 95% CI, P¼ 0.016) and a per-exposure
risk reduction of 80.6%, consistent with prior studies5. The
Ad35/Ad26/Env group demonstrated 83% complete protection
with a Cox proportional hazard ratio of 0.114 (0.024–0.541 95%
CI, P¼ 0.006) and a per-exposure risk reduction of 88.6%.
Therefore, in the RLD challenge model, both vaccinated arms
showed robust protection against acquisition of infection.
Comparing the number of T/F variants between vaccine arms
is a direct measure of vaccine efﬁcacy and can be integrated with
acquisition data to provide a more comprehensive view of vaccine
protection3. We therefore performed single genome ampliﬁcation
(SGA) and sequence analysis to determine the number of
transmitted/founder (T/F) viruses in each animal. We obtained
319 full-length env sequences and inferred the number of
T/F genomes by phylogenetically comparing all sequences from
infected animals as well as from the original virus inoculum
(Supplementary Fig. 1A). This composite tree was used as a guide
to distinguish closely related viruses and identify independent
infection events. All sequences from each animal were also
analysed individually using phylogenetic approaches and visual
inspection of alignments (Supplementary Fig. 1B–D), as well
as mathematical models of early viral diversiﬁcation10,11,15,16.
Using this approach, individual lineages representing unique
T/F genomes that established systemic infection were inferred.
The number of T/F variants detected in the plasma of all animals
ranged from a single variant to 3 identiﬁable variants (Fig. 3a).
The median number of variants initiating infection in sham
controls was 1 (mean of 1.2; range 0–3), which was signiﬁcantly
reduced in the Ad35/Ad26 arm, which had a median number
of variants of 0 (mean 0.33; range 0–2; P¼ 0.001, Wilcoxon
rank-sum test) and was further reduced in the Ad35/Ad26/Env
arm with a median number of variants of 0 (mean 0.17;
range 0–1; P¼ 0.001, Wilcoxon rank-sum test). There is no
signiﬁcant difference between vaccinated groups (P¼ 0.423,
Wilcoxon rank-sum test). The relatively low number of
T/F variants in all groups is consistent with the RLD challenge
model and highlights the uniformity of infection utilizing
this approach.
We next sought to assess the differences in protective effects
of each vaccine stratiﬁed by their neutralization genotype:
neutralization resistant A/K or neutralization sensitive non-A/K
(Supplementary Fig. 2; Table 2). For the ten of twelve infected
control animals, eight were neutralization sensitive (non-A/K)
and two were neutralization resistant (A/K). For the three of
twelve infected Ad/Ad animals, two were neutralization sensitive
(non-A/K) and one was neutralization resistant (A/K). For the
two of twelve infected Ad35/Ad26/Env (Ad/Prot) animals,
both were neutralization resistant (A/K). We found a signiﬁcant
protective effect in both vaccine arms when comparing total
infection events and non-A/K viruses. However, there was
insufﬁcient power to evaluate a potential vaccine effect on
A/K viruses as a result of the low number of infections in
the vaccinated animals (three and two infection events for
Ad35/Ad26 only and Ad35/Ad26/Env, respectively). The results
were largely invariant to choice of statistical models and varied
statistical assumptions (Table 2). Therefore, while both vaccines
in the RLD study showed statistically signiﬁcant protection and
a reduction in the number of T/F viruses, there was insufﬁcient
power to assess protection speciﬁcally against neutralization-
resistant A/K variants due to the high level of protection observed
in this study.
Single high-dose challenge study. We reasoned that a high-dose
viral challenge should result in increased infection events
that would facilitate the sieve analysis and thus may allow
for an assessment of vaccine efﬁcacy speciﬁcally against
neutralization-resistant A/K SIVsmE660 variants. Therefore, in
Study 2 (SHD challenge study), 30 rhesus monkeys were grouped
into three arms (N¼ 10 per group) and received the same
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Figure 2 | Protective efﬁcacy. The number of challenges required for
detection of productive infection for each vaccine group. Kaplan–Meier plot
indicates the percent of uninfected animals after each challenge. Ad/Env
(blue) indicates animals primed with Ad35/Ad26 and boosted with
adjuvanted Env gp140 (Ad35/Ad26/Env). Ad/Ad (red) indicates animals
vaccinated with Ad35/Ad26 only. The RLD challenge study (a) shows
infections over time with protection in 75% of Ad/Ad vaccinated animals
and 85% of Ad/Env vaccinated animals. The SHD challenge study
(b) shows infections in all control animals and protection in 20% of Ad/Ad
vaccinated animals and in 40% protection in Ad/Env vaccinated animals.
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vaccines as in Study 1: Ad35/Ad26 only, Ad35/Ad26/Env or
sham controls. Humoral and cellular immune responses
were comparable with the prior study (Supplementary Fig. 3;
Supplementary Table 1). In this study, all animals had
resistant TRIM5a alleles except one animal in each vaccine group.
Animals were then challenged by the intrarectal route with a
single 9.3 105 TCID50 dose of undiluted SIVsmE660, which
is 1,000-fold higher than the dose used in Study 1 (RLD challenge
study). All 10 sham vaccinated animals were infected after this
single, high-dose challenge. In contrast, eight of ten Ad35/Ad26
vaccinated animals and only six of ten Ad35/Ad26/Env vacci-
nated animals became infected (Fig. 2b). Protection against
acquisition of infection was signiﬁcant in the Ad35/Ad26/Env
group (40%; P¼ 0.043, Fisher’s exact test) but not in the
Ad35/Ad26 group (20%; P¼ 0.237, Fisher’s exact test) (Table 1).
These data suggest that the Env protein boost was important for
optimizing protective efﬁcacy against high-dose challenge with
SIVsmE660.
We next identiﬁed the number and genetic characteristics
of all T/F variants following challenge in this study. After the
SHD challenge, the median number of T/F variants was seven
in the sham controls (mean 6.7, range 1–13), which was
signiﬁcantly reduced in the Ad35/Ad26 vaccinated animals to a
median of only two variants (mean 2.7; range 0–10, P¼ 0.04,
Poisson regression), and further reduced in the Ad35/Ad26/Env
vaccinated animals to a median of 1 variant (mean 1.3; range
0–4, P¼ 0.014, Poisson regression) (Fig. 3b). Increasing the total
number of T/F variants with the SHD challenge model allowed
us to quantitate more clearly the reduction in the number
of variants establishing infection in the vaccinated arms.
Interestingly, using a fractional polynomial regression model,
we identiﬁed a strong, non-linear relationship between the
number of T/F variants and peak viremia (Po0.001, likelihood
ratio test).
Evaluation of breakthrough infections. We next evaluated
breakthrough infections in both the RLD and SHD studies. We
identiﬁed 118 T/F variants in total (15 from Ad35/Ad26/Env
vaccinees, 31 from Ad35/Ad26 vaccinees, and 72 from sham
controls). Genetic sieve analysis was performed using the inferred
amino acid translation over the entire Env for all 118 T/F
genomes, as well as 66 inoculum sequences. Each T/F lineage was
compared to the consensus sequence of the stock and plotted
as a fraction of this consensus for each vaccine group (Fig. 4).
Fisher’s Exact Permutation Test was then used to identify the
sites with signiﬁcant differences between vaccinated and sham
controls. In total, 41 sites were identiﬁed as informative with
more than one T/F genome containing polymorphisms at
each site (Supplementary Table 2). The vast majority of all
41 polymorphisms were apparent in both vaccinated and control
animals indicative of random variation without vaccine selection.
However, there were a few sites statistically enriched only in
vaccinated animals. These include three single amino acid
mutations (T45A, R47K, S70N) that were statistically enriched in
both Ad35/Ad26 and Ad35/Ad26/Env vaccinated animals. The
asparagine at site 70 produces a potential N-linked glycosylation
(PNG) site and is found in only 21% of the stock sequences. This
minor population was signiﬁcantly enriched in breakthrough
viruses representing 90% of T/F viruses in the Ad35/Ad26 group
(P¼ 0.001 compared to sham, Fisher’s exact test) and 93% of
T/F in the Ad35/Ad26/Env arm (P¼ 0.008 compared to sham,
Fisher’s exact test). The neutralization resistant A/K genotype
(T45A, R47K) was also highly enriched in breakthrough viruses
Table 1 | Protective efﬁcacy of Ad35/Ad26/Env and Ad35/Ad26 vaccines against RLD and SHD SIVsmE660 challenges.
Challenge Vaccine Complete
protection*
P value versus
Sham
Hazard ratio (95% conﬁdence
interval)
Per-exposure risk
reduction
Repetitive low-dose (RLD) Ad35/Ad26/Env 83% 0.006w 0.114 (0.024–0.541) 88.6%
Ad35/Ad26 75% 0.016w 0.194 (0.051–0.072) 80.6%
Sham 16% N/A 1 N/A
Single high-dose (SHD) Ad35/Ad26/Env 40% 0.043z N/A N/A
Ad35/Ad26 20% 0.237z N/A N/A
Sham 0% N/A N/A N/A
*Percent uninfected animals after 12 intrarectal challenges.
wCox proportional hazard model.
zFisher’s exact test.
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Figure 3 | Transmitted/founder analysis. The total number of T/F
genomes was determined in each animal in the RLD (a) and SHD
(b) challenge studies. Average and standard error are indicated. Signiﬁcant
differences in mean number of variants by Wilcoxon rank-sum tests are
shown. Ad/Env (blue) indicates animals primed with Ad35/Ad26 and
boosted with adjuvanted Env gp140 (Ad35/Ad26/Env). Ad/Ad (red)
indicates animals vaccinated with Ad35/Ad26 only. Difference between
vaccinated groups were not signiﬁcant (n.s.).
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in vaccinated animals. We found the A/K genotype in 68% of the
T/F viruses in the Ad35/Ad26 group (P¼ 0.001 compared with
sham, Fisher’s exact test) and in 73% of the T/F in the
Ad35/Ad26/Env group (P¼ 0.007 compared to sham, Fisher’s
exact test). In addition to these single amino acid polymorphisms,
length variation within the V1 loop was also associated with
breakthrough infections in Ad35/Ad26 vaccinated animals
(P¼ 0.015 compared to sham, Fisher’s exact test) and
Ad35/Ad26/Env vaccinated animals (P¼ 0.035 compared with
sham, Fisher’s exact test). Therefore, genetic sieve analyses of T/F
viruses from vaccinated and control animals revealed selection of
viruses in vaccinated animals with a critical N-linked glycan, an
increase in proportion of neutralization-resistant A/K viruses,
and mutations within variable loops. Taken together, these data
provide evidence for vaccine-elicited protection with the greatest
selection seen in the Ad35/Ad26/Env vaccinated animals.
We next sought to assess the differences in protective effects
of each vaccine stratiﬁed by their neutralization genotype:
neutralization resistant A/K or neutralization sensitive non-A/K.
This analysis could only be performed in the SHD study as a
result of the increased number of infection events. Protective
effects against neutralization-resistant A/K viruses were
expressed, as incidence rate ratios (IRR) and assessed using a
Poisson regression model (Table 3). As expected, analysis of
the neutralization-sensitive non-A/K variants demonstrated
signiﬁcantly lower IRRs compared with sham controls in both
Ad35/Ad26 (Po0.001, Poisson regression) and Ad35/Ad26/Env
(Po0.001, Poisson regression) vaccinated animals. Remarkably,
in the neutralization-resistant A/K analysis, we also observed a
signiﬁcant reduction in the IRR compared with sham controls in
the Ad35/Ad26/Env vaccinated animals (P¼ 0.050, Poisson
regression), but not in the Ad35/Ad26 vaccinated animals
(P¼ 0.876, Poisson regression). The two animals with a
permissive TRIM5a genotype were protected and thus did not
impact this sieve analysis. These data demonstrate that the Env
gp140 protein boost was required to block the A/K neutraliza-
tion-resistant variants within the SIVsmE660 swarm.
We evaluated neutralizing antibody activity in the vaccinated
animals against both the non-AK neutralization-sensitive tier 1
SIVsmE660 clone (CP3C-P-A8) and the AK neutralization-
resistant tier 2 SIVsmE660 clone (CR54-PK-2A5). The vaccine
induced high tier 1 NAb titres and low but detectable tier 2 NAb
responses, which are reported as % neutralization. As shown in
Fig. 5, the protected animals induced higher tier 2 NAb responses
to the AK neutralization-resistant variant CR54-PK-2A5, as
compared with the infected animals at week 52 (P¼ 0.007,
Wilcoxon rank-sum test), which is consistent with the sieve
analysis. Taken together, these data demonstrate that the
Ad35/Ad26/Env vaccine afforded 40% protection against
acquisition of a heterologous, single, high-dose challenge
with SIVsmE660 and blocked not only neutralization-sensitive
non-A/K viruses but also neutralization-resistant A/K viruses
within the swarm.
Discussion
We recently reported that an Ad26-Gag/Pol/Env prime,
Env gp140 boost vaccine afforded 50% efﬁcacy against
heterologous RLD challenges with neutralization-resistant SIV-
mac251 (ref. 6). In the present study, we conﬁrmed and extended
these ﬁndings using an Ad-Gag/Pol/Env prime, Env gp140 boost
vaccine against heterogeneous RLD and SHD challenges with
SIVsmE660. The Ad prime, Env protein boost vaccine
signiﬁcantly protected 40% of animals against the high-dose
SIVsmE660 challenge. Using a sieve analysis of the T/F viruses,
we demonstrated that this vaccine protected not only against
neutralization-sensitive non-A/K viruses but also against
neutralization-resistant A/K viruses. To the best of our
knowledge, this is the ﬁrst report of protection against
neutralization-resistant A/K variants within the SIVsmE660
swarm by any vaccine. These data highlight the protective
efﬁcacy of the Ad prime, Env protein boost vaccine and suggest
the importance of the Env protein boost in blocking neutra-
lization-resistant viral variants.
Protection against RLD SIVsmE660 challenges has also been
reported for a DNA prime, Ad5 boost vaccine3. In this prior
study, no protection was observed against neutralization-resistant
A/K variants within the SIVsmE660 swarm. In the present study,
we observed protection against both RLD and SHD SIVsmE660
challenges, and the sieve analysis revealed that there were only a
limited number of sites under selection pressure following
transmission in vaccinated animals. These included the A/K
sites at positions 45/47, which were initially postulated3 and
subsequently proven4 to confer a neutralization-resistant pheno-
type. We also found evidence of selection of an N-linked glycan at
position 70 that was signiﬁcantly enriched in vaccinated animals.
Altogether, this A-K-N genotype in breakthrough viruses suggests
that vaccine efﬁcacy was antibody mediated.
We previously reported signiﬁcant differences between diverse
SIVmac251 stocks17. In contrast, SIVsmE660 is generally more
homogeneous with most stocks containing overlapping viral
genomes. One exception is a prior study in which an SIVsmE660
Table 2 | Cox and exact logistic regression models for protection against all T/F Genomes, A/K-only genomes, or non-A/K
genomes in the RLD challenge study.
Group No. of
animals
Log-rank test
(P-value)
Cox model Exact logistic regression model
Haz. Ratio Lower 95% CI Upper 95% CI P value Odds ratio Lower 95% CI Upper 95% CI P value
Total
Infections
Sham 12 Ref. Ref. Ref.
Ad35/Ad26 12 0.0092 0.194 0.051 0.735 0.016 0.077 0.005 0.647 0.0123
Ad35/Ad26/Env 12 0.0010 0.114 0.024 0.541 0.006 0.049 0.003 0.454 0.0033
All versus Sham 24 versus 12 0.0002 0.152 0.049 0.464 0.001 0.059 0.005 0.393 0.0011
Non AK only Sham 11 Ref. Ref. Ref.
Ad35/Ad26 12 0.0112 0.161 0.033 0.784 0.024 0.0867 0.0058 0.7444 0.0202
Ad35/Ad26/Env 12 0.0002 0.0326 0 0.2711 0.0007
All versus Sham 24 versus 11 0.0001 0.076 0.016 0.378 0.001 0.0400 0.003 0.3137 0.0005
AK only Sham 11 Ref. Ref. Ref.
Ad35/Ad26 12 0.446 0.368 0.032 4.252 0.424 0.425 0.006 9.423 0.932
Ad35/Ad26/Env 12 0.697 0.682 0.091 5.133 0.710 0.904 0.055 14.949 1.000
All versus Sham 24 versus 11 0.494 0.531 0.084 3.342 0.500 0.651 0.063 9.053 1.000
The bold entries indicate signiﬁcant P values.
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stock had an unusually low frequency of neutralization-resistant
A/K viruses18. In that study, there was no evidence of selection
for A/K viruses with a DNA prime, MVA boost vaccine likely
due to the limited proportion of A/K variants in the stock (5%).
While these authors found an enrichment in all transmission
events for A/K viruses, there was no increase in selection in
vaccinated animals. It was suggested that all founder viruses are
enriched for the A/K genotype18,19. While we also found an
enrichment in the A/K genotype compared to the stock, the
vaccine effect we report here was a statistically signiﬁcant increase
in the A/K genotype in vaccinated animals compared to sham
controls. Therefore, while A/K viruses are likely found more often
in all infection events, its further enrichment is indicative of a
vaccine protective effect. Importantly, when the A/K genotype
was ﬁrst reported in a DNA prime, Ad5 boost immunization
study3, Roederer et al. found that 23.5% of that stock contained
the resistant A/K form of the virus. In the SIVsmE660 stock
reported here, 21% of viruses contained the resistant A/K
genotype, which allowed for both a meaningful sieve analysis
and direct comparisons between studies. Therefore, unlike the
DNA prime, Ad5 boost study3, we found signiﬁcant protection
against neutralization-resistant A/K viruses in the SIVsmE660
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Figure 4 | Genetic sieve analysis. The entire Env proteome for each T/F virus and all stock sequences were compared to the consensus sequence of the
stock. All 41 informative sites are plotted as the proportion of each amino acid relative to the consensus sequence of the stock. Gene regions are colour
coded and labelled. For most sites, the majority of T/F virus sequences match the stock consensus sequence. However, amino acids 45, 47 and 70 showed
signiﬁcant enrichment in vaccinated animals demonstrating the sieve effect for viruses with nonconsensus changes at these sites. Statistical comparisons
for all sites are shown in Supplementary Table 2.
Table 3 | Effects of Ad35/Ad26 and Ad35/Ad26/Env vaccination on the number of T/F variants divided into A/K or non-A/K
genotypes in the SHD challenge study.
Group IRR for non-AK variants IRR for AK variants P value for equivalence test*
IRR Lower 95%CI Upper 95%CI P value IRR Lower 95%CI Upper 95%CI P value
Sham Ref. Ref.
Ad35/Ad26 0.171 0.080 0.365 o0.001 0.950 0.499 1.810 0.876 o0.001
Ad35/Ad26/Env 0.086 0.031 0.239 o0.001 0.450 0.202 1.002 0.050 0.004
IRR, incidence rate ratio.
*P value for testing equivalence of IRRs for AK and non-AK variants.
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swarm using comparable virus stocks. These data are consistent
with our previous ﬁndings with SIVmac251, in which most of the
viruses in the SIVmac251 stock are neutralization-resistant6.
The ability to protect against neutralization-resistant viruses
within a swarm is important for a candidate HIV-1 vaccine, since
many primary isolate viruses contain neutralization-resistant
viruses. Moreover, our ﬁndings show the utility of genetic sieve
analyses in analysing vaccine efﬁcacy to gain a greater level of
understanding beyond the overall protective efﬁcacy of the
vaccine. Together with our previous study6, the Ad prime, Env
protein boost strategy has shown protection in multiple challenge
models (RLD SIVmac251, RLD SHIV-SF162P3, RLD
SIVsmE660, SHD SIVsmE660), thus supporting further clinical
development of this vaccine concept.
Methods
Immunizations and challenges. Indian-origin, outbred, young adult, male and
female, speciﬁc pathogen-free (SPF) rhesus monkeys (Macaca mulatta) that did
not express the controlling class I alleles Mamu-A*01, Mamu-B*08 and
Mamu-B*17 were housed at the New England Primate Research Center (NEPRC),
Southborough, Massachusetts, USA. A total of 66 animals were used for both
studies. Groups were balanced for susceptible and resistant TRIM5a alleles1,20.
Immunizations were performed by the intramuscular route in the quadriceps
muscles with 2 1010 viral particles of Ad35 or Ad26 vector14 expressing
SIVmac239 Gag-Pol and Env (gp140). Ad35/Ad26 vaccinated animals were primed
with Ad35 at week 0 and boosted with Ad26 at week 24. Ad35/Ad26/Env
vaccinated animals were primed with Ad35 at week 0 and boosted with Ad26 at
week 24 and then given 0.25mg of SIVmac32H Env gp140 (ref. 21) with GSK
Adjuvant System AS01B at weeks 36, 40 and 44. To evaluate protective efﬁcacy and
immunological correlates, repetitive, low-dose (RLD) challenges were performed
beginning at week 52 with 12 intrarectal inoculations of the heterologous virus
SIVsmE660 (ref. 1) using a 1:1,000 dilution (930 TCID50) of our challenge stock.
Monkeys were bled weekly for viral loads (Siemans Diagnostics), and the date of
infection was deﬁned as the last challenge time point before the ﬁrst positive SIV
RNA level. SHD challenges were performed with a 9.3 105 TCID50 dose of
undiluted virus administered intrarectally. In the SHD challenge study, all animals
had resistant TRIM5a alleles except one animal in each vaccine group. Animals
were followed to determine set point viral loads. All animal studies were approved
by the Harvard Medical School Institutional Animal Care and Use Committee
(IACUC).
Cellular and humoral immune assays. SIV-speciﬁc cellular immune responses
were assessed by IFN-g ELISPOT assays essentially, as described in ref. 22.
ELISPOT assays used pools of SIVsmE543 and SIVmac239 Gag, Pol and Env
peptides. Peptides were 15 amino acids in length and overlapped by 11 amino
acids. Spot-forming cells (SFC) in 200,000 peripheral blood mononuclear cells
(PBMC) were assessed separately in response to Gag, Pol and Env peptide pools.
Total responses were deﬁned as the sum of Gag, Pol, and Env responses and were
normalized to SFC per million PBMC. SIV-speciﬁc humoral immune responses
were assessed by SIVmac251 Env ELISA and TZM-bl pseudovirus neutralization
assays essentially, as described in refs 1,23.
Single genome ampliﬁcation and T/F enumeration. From each plasma
specimen and the challenge inoculum, viral RNA was extracted using the
QIAamp Viral RNA Mini kit (Qiagen). RNA was eluted and immediately subjected
to cDNA synthesis. Reverse transcription of RNA to single-stranded cDNA was
performed using 1 RT buffer, 0.5mM of each deoxynucleoside triphosphate,
5mM dithiothreitol, 2 Uml 1 RNaseOUT (RNase inhibitor), 10Uml 1 of
SuperScript III reverse transcription and 0.25mM antisense primer SIVsmEnvR1
50-TGT AAT AAA TCC CTT CCA GTC CCC CC-30 (nt 9454–9479 in
SIVmac239). The mixture was incubated at 50 C for 60min, followed by an
increase in temperature to 55 C for an additional 60min. The reaction was then
heat-inactivated at 70 C for 15min and treated with 2U of RNAse H at 37 C for
20min. The newly synthesized cDNA was used immediately or frozen at  80 C.
cDNA was serially diluted and distributed among 96-well plates so as to identify a
dilution where PCR-positive wells constituted o30% of the total number of
reactions. PCR ampliﬁcation was performed in the presence of 1High
Fidelity Platinum PCR buffer, 2mM MgSO4, 0.2mM of each deoxynucleoside
triphosphate, 0.2 mM of each primer and 0.025U ml 1 Platinum Taq High
Fidelity polymerase in a 20-ml reaction (Invitrogen). First round PCR primers
included sense primer SIVsmEnvF1 50-CCT CCC CCT CCA GGA CTA GC-30
(nt 6127–6146 in SIVmac239) and antisense primer SIVsmEnvR1. PCR was
performed with the following parameters: 1 cycle of 94 C for 2min, 35 cycles of a
denaturing step of 94 C for 15 s, an annealing step of 55 C for 30 s, and an
extension step of 68 C for 4 min, followed by a ﬁnal extension of 68 C for 10min.
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Figure 5 | Correlation of protective efﬁcacy with neutralizing antibody responses. Neutralizing antibody responses are shown at week 0 (a,c) and
week 52 (b,d) in the vaccinated animals against both the non-AK neutralization-sensitive tier 1 SIVsmE660 clone (CP3C-P-A8) and the AK
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Next, 1 ml from ﬁrst-round PCR product was added to a second-round PCR
reaction that included the sense primer SIVsmEnvF2 50-TAT GAT AGA CAT
GGA GAC ACC CTT GAA GGA GC-30 (nt 6292–6323 in SIVmac239) and
antisense primer SIVsmEnvR2 50-ATG AGA CAT RTC TAT TGC CAA TTT
GTA-30 (nt 9413–9439 in SIVmac239). The second-round PCR reaction was
performed under the same conditions used for ﬁrst-round PCR, but with a total of
45 cycles. All PCR procedures were performed under PCR clean room conditions
using procedural safeguards against sample contamination, including prealiquoting
of all reagents, use of dedicated equipment, and physical separation of sample
processing from pre- and post-PCR ampliﬁcation steps. Correctly sized amplicons
determined by electrophoresis on an agarose gel were directly sequenced by
cycle-sequencing using BigDye terminator chemistry and protocols recommended
by the manufacturer (Applied Biosystems). Individual sequence fragments for each
amplicon were assembled and edited using Sequencher (Gene Codes). Inspection of
individual chromatograms allowed for the conﬁrmation that amplicons were
derived from a single viral template. The absence of mixed bases at each nucleotide
position throughout the entire env gene was taken as evidence of SGA from a single
vRNA/cDNA template. This quality control measure allowed us to exclude from
the analysis amplicons that resulted from PCR-generated in vitro recombination
events or Taq polymerase errors and to obtain individual env sequences that
proportionately represent those virions circulating in vivo.
All sequence alignments and phylogenetic trees were performed in ClustalW
with manual editing in MacClade. Each low-diversity lineage was compared with a
mathematical model of viral diversiﬁcation overtime to identify all transmitted/
founder lineages, as previously described in ref. 10. The number of TF variants was
determined by sequence analysis (phylogenetic trees and highlighter plots)
comparing all sequences within an individually infected animal with and without
stock sequences. The number of variants identiﬁed were conﬁrmed using a
phylogenetic tree of all sequences combined. The average number of sequences
analysed per animal was 22 (range 16–26) with no signiﬁcant differences in
the number of sequences between groups (P¼ 0.4 ANOVA) and no correlation
between the number of TF and the number of sequences per animal
(P¼ 0.73 Pearson).
Sieve analysis. Each T/F variant from all infected animals (total of 118 T/F
lineages), as well as 66 stock sequences were used to generate a consensus
amino acid sequence. Each T/F lineage was then compared with the consensus and
plotted as a fraction of the consensus for each vaccine group regardless of challenge
dose. In total, 41 sites were identiﬁed as informative excluding single sequence
polymorphisms. Fisher’s Exact/Permutation Tests with Bonferroni corrections
were utilized to identify signiﬁcant enrichment of amino acids at each of
these 41 sites.
Statistical analyses. Protection against acquisition of infection was analysed
using the Cox proportional hazards model with exact partial-likelihood method to
handle tied failures. The number of repeated challenges from inoculation to the
earliest detection of SIV infection or censorship was analysed, as a discrete time
variable in the Cox regression models. The number of challenges required for 50%
infection of each group, hazard ratios with 95% conﬁdence intervals, per-exposure
vaccine efﬁcacy and per-exposure risks of infection were quantiﬁed. Vaccine
efﬁcacy was deﬁned as the reduction in the per-exposure probability of infection
as previously described in refs 24,25. Protection against all T/F, A/K only or
non-A/K genomes by experimental group were analysed using log-rank tests, Cox
proportional hazards model and exact logistic regression model. For the analysis of
the vaccine effects on number T/F, A/K or non-A/K variants per animal, Poisson
regression models were used. Uninfected animals were coded as 0 counts of
variants26–28. Protective effects are expressed as incidence rate ratios (IRR). We
then used simultaneous estimation equations to compare the equivalence of
protective effects against all T/F, A/K or non-A/K virus. Fisher’s exact permutation
test was used to compare differences in non-consensus rates between experimental
groups. Bonferroni corrections were applied to the eight tests on each site, and a
threshold of Po0.00625 was therefore used to determine statistical signiﬁcance.
The association of the peak viral load with number of T/F was analysed using
fractional polynomial regression models. A strong non-linear association between
the two variables was detected. To properly model the relationship, we transformed
the number of T/F value (X) as its inverse (1/X), and used 1/X as the predictor.
Wilcoxon rank-sum tests were utilized to compare neutralizing antibody titres in
protected versus infected vaccinated animals at week 52.
Data availability. All 813 sequences from infected animals are deposited in
GenBank under accession numbers KP237051–KP237863 and 66 stock sequences
KX360059–KX360124. All other relevant data are available from the authors upon
request.
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